DadFinStart your free week
DadFin › Stocks › Healthcare › RDY

Dr. Reddy's Laboratories Limited (RDY) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · India

$12.48 ▲ +2.30% today

28.5
Dad Score, out of 100
weak

Dr. Reddy's Laboratories Limited (RDY) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in India. On DadFin's weekly run it scores 28.5 out of 100 on the Dad Score, a weak reading that places the business ahead of 29% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #644 of 974. Its strongest axes are price action, risk and liquidity; its weakest are valuation and quality.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Below average
Growth
Weak
Price action
Above average
Risk
Above average
Conviction
Weak
Liquidity
Above average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)29.9×
P/E (forward)18.9×
Dividend yield0.68%
Return on capital14.3%
Operating margin4.2%
Revenue growth (YoY)+3.2%
FCF yield25.0%
Net debt / EBITDA-0.17×
Piotroski F-Score4 / 9
52-week change-12.4%
Market cap$10.2B
Next earningsOct 23, 2026

What subscribers see on RDY

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.